It\u2019s one of those industry mantras that\u2019s been around for years \u2014 a quiet warning to manufacturers that a simpler, faster, or less frequent treatment with similar efficacy and safety probably won\u2019t move the needle on coverage or access.<\/p>\n
Maybe it\u2019s time we start questioning that.<\/p>\n
Route and frequency of administration are an essential part of competitive product strategy for patients and providers. However, payers have very different attitudes, preferences, and incentives, and require distinct engagement strategies.<\/p>\n
In this series of posts, we\u2019ll explore examples where payers are rewarding new routes\/frequencies of administration with premium access or pricing. Because what we\u2019ve long dismissed as \u201cconvenience\u201d \u2014 fewer clinic visits, simpler administration, better adherence \u2014 may represent value by another name.<\/p>\n
The challenge lies in how new routes and frequency of administration are positioned \u2014 and perceived \u2014 by payers.<\/p>\n
INVEGA HAFYERA, UZEDY, and ABILIFY ASTIMTUFII are long-acting injectable (LAI) therapies for schizophrenia that contain the same active ingredient as commonly prescribed generic oral therapies. These LAIs are administered 2-6 times per year by a healthcare provider and are substantially more expensive than their oral counterparts. There is no direct evidence in pivotal clinical trials that INVEGA HAFYERA, UZEDY, and ABILIFY ASTIMTUFII are superior to daily orals with with the same active ingredient,[1]<\/a><\/sup> yet payers widely cover these drugs.<\/p>\n How did manufacturers make the case that the price premium was justified, particularly for budget-sensitive Medicaid plans? They skipped past convenience = adherence arguments and demonstrated better real-world outcomes and 43% lower overall health costs over 2 years.[3]<\/a><\/sup><\/strong><\/p>\n But what happens in therapeutic areas where cost savings are more difficult to demonstrate? The migraine prophylaxis market presents a different perspective on how payers respond to new routes and dosing schedules.<\/p>\n QULIPTA is a daily oral treatment for migraine prophylaxis that was launched as an alternative treatment option to long-acting IV or subcutaneous injections that target the same pathway. QULIPTA had similar reductions in monthly migraine days to AIMOVIG, AJOVY, and EMGALITY in pivotal clinical trials.[4]<\/a><\/sup><\/p>\n Here\u2019s the striking part: QULIPTA\u2019s list price is roughly 50% higher than AIMOVIG, AJOVY, and EMGALITY,[5]<\/a><\/sup> yet it enjoys the highest coverage rate among Medicare Advantage plans and comparable coverage in commercial plans.<\/p>\n At first glance, this seems counterintuitive. Adherence to daily oral migraine prophylaxis is known to be among the lowest across treatment options, according to recent real-world data from Clarivate.[6]<\/a><\/sup><\/p>\n So, what\u2019s driving coverage here? Likely factors include market dynamics, plan design, rebates and discounts, and the flexibility that daily orals offer in managing the overall benefit mix.<\/p>\n Therapies with new routes\/frequency of administration have multiple options to demonstrate payer value beyond clinical outcomes and cost savings. <\/strong>Understanding the implications to benefit design can be critical to success. However, not every case rewards convenience.<\/p>\n ENTYVIO, for ulcerative colitis and Crohn\u2019s disease, is available as a monthly IV and a bi-monthly autoinjector. IV and autoinjector have similar efficacy and safety profiles, but the autoinjector\u2019s list price is 40% higher than the IV.<\/p>\n Coverage tells a clear story:<\/p>\n Here, payers<\/strong> do not appear willing to pay for convenience alone<\/strong>. However, the difference between Medicare Advantage and commercial coverage hints that patient population and benefit design still influence access decisions<\/strong>. Convenience interacts with other factors, but it isn\u2019t sufficient on its own to drive premium coverage.<\/p>\n Payer acceptance of a route or frequency of administration is context-dependent. <\/strong>At Clarivate, we\u2019ve identified four factors that can support premium pricing or access for products offering new routes or frequencies of administration:<\/p>\n In the coming posts, we\u2019ll take a closer look at each of these dynamics \u2014 and explore when and how \u201cconvenience\u201d becomes something payers really do<\/em> pay for.<\/p>\n Clarivate\u2019s experienced market access and pricing experts can help you analyze, optimize, and tailor your strategy to maximize commercial success. Visit us to learn more or connect with our experts: <\/em>Healthcare Commercial Consulting Services | Clarivate<\/em><\/a><\/p>\n <\/p>\n This post was written by Moira Ringo, Director, Commercial Consulting, and Leyla Jiang, Senior Consultant, Commercial Consulting<\/em><\/p>\n <\/p>\n [1]<\/a> Unless otherwise indicated, efficacy and safety data can be found in the FDA label (i.e., Highlights of Prescribing Information) for each therapy<\/small><\/p>\n [2]<\/a> DRG Fingertip Formulary accessed October 2025<\/small><\/p>\n [3]<\/a> Fu, A.Z., Pesa, J.A., Lakey, S.\u00a0et al.<\/em>\u00a0Healthcare resource utilization and costs before and after long-acting injectable antipsychotic initiation in commercially insured young adults with schizophrenia.\u00a0BMC Psychiatry<\/em>\u00a022, 250 (2022). https:\/\/doi.org\/10.1186\/s12888-022-03895-2<\/small><\/p>\n [4]<\/a> Highlights of Prescribing Information for QULIPTA, AIMOVIG, AJOVY, and EMGALITY<\/small><\/p>\n [5]<\/a> NAVLIN pricing database accessed October 2025<\/small><\/p>\n\n
Case study 2: Daily orals vs. long-acting injectables in migraine prevention<\/strong><\/h3>\n
Case study 3: When convenience doesn\u2019t command a premium<\/strong><\/h3>\n
\n
The takeaway<\/strong><\/h3>\n
\n